Guangshengtang: New crown drug Taizhongding has superior anti-new crown virus efficacy
Read Time:35 Second
On January 9, KWS announced that the investigator-initiated clinical study (IIT) summary report was completed and obtained for Tazedin (Teatrovir GST-HG171 tablets in combination with ritonavir tablets), a first-in-class, oral, small-molecule, innovative anti-neocolonavirus drug. The results of the study showed that Tezongdin has superior anti-NeoCretavirus efficacy, and the time to nucleic acid regression in patients with NeoCreta was significantly better than the positive control Paxlovid and placebo control, while the safety and tolerability were good, meeting the expected objectives of the trial. The Company has fully initiated the Phase II/III pivotal registration clinical study of Taizhongding and is currently recruiting subjects at more than 30 centers nationwide.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating